Estimations nationales incidence et mortalite par cancer en France métropolitaine entre, 1990. ,
International Variation in Female Breast Cancer Incidence and Mortality Rates, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.24, pp.1495-506, 2015. ,
Combined chemotherapyradiotherapy approach in locally advanced (T3b-T4) breast cancer, Cancer Chemother Pharmacol, vol.1, pp.53-62, 1978. ,
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18, J Clin Oncol Off J Am Soc Clin Oncol, vol.15, pp.2483-93, 1997. ,
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902, J Clin Oncol Off J Am Soc Clin Oncol, vol.19, pp.4224-4261, 2001. ,
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, pp.778-85, 2008. ,
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, vol.97, pp.188-94, 2005. ,
Facteurs prédictifs de traitement conservateur après chimiothérapie néo-adjuvante dans le cancer du sein, Gynécologie Obstétrique Fertil Sénologie, vol.45, pp.466-71, 2017. ,
Effect of Neoadjuvant Chemotherapy on the Surgical Treatment of Patients With Locally Advanced Breast Cancer Requiring Initial Mastectomy, Clin Breast Cancer, vol.15, pp.231-235, 2015. ,
A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility, Ann Surg Oncol, vol.9, pp.228-262, 2002. ,
Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy, Cancer Res Treat, vol.47, pp.197-207, 2014. ,
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer, JAMA, vol.305, pp.1873-81, 2011. ,
Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database, Ann Surg Oncol, vol.24, pp.1507-1522, 2017. ,
Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment, Breast Care Basel Switz, vol.12, pp.102-109, 2017. ,
De-escalating and escalating treatments for early-stage breast cancer: the St, Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer, vol.28, pp.1700-1712, 2017. ,
Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment, Breast Care, vol.2019, pp.1-8 ,
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, pp.164-72, 2014. ,
Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients, Gen. Sess. Abstr, pp.2-03, 2019. ,
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, pp.2433-2476, 2018. ,
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med, vol.380, pp.617-645, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02464524
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment, Clin Cancer Res, vol.10, pp.6622-6630, 2004. ,
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy, Eur J Cancer Oxf Engl, vol.40, pp.205-216, 1990. ,
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy, Eur J Cancer Oxf Engl, vol.39, pp.438-484, 1990. ,
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, pp.1037-1081, 2006. ,
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer, Breast Cancer Res Treat, vol.142, pp.227-262, 2013. ,
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, pp.2600-2608, 2003. ,
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.3676-85, 2005. ,
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet Lond Engl, vol.375, pp.377-84, 2010. ,
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort, Br J Cancer, vol.114, pp.44-52, 2016. ,
Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.11, pp.5678-85, 2005. ,
Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, vol.100, pp.8418-8441, 2003. ,
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials, Breast Cancer Res Treat, vol.152, pp.377-87, 2015. ,
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials, Breast Cancer Res Treat, vol.150, pp.127-166, 2015. ,
The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis, PloS One, vol.9, p.115103, 2014. ,
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, vol.125, pp.145-56, 2011. ,
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, pp.2019-2046, 2006. ,
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer, Cancer, vol.107, pp.1459-66, 2006. ,
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer, J Clin Oncol, vol.23, pp.8331-8340, 2005. ,
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial, Ann Surg, vol.260, pp.614-616, 2014. ,
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer, Breast Cancer Res Treat, vol.142, pp.227-262, 2013. ,
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer, Breast Cancer Res Treat, vol.136, pp.35-43, 2012. ,
Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy, Ann Surg Oncol, vol.22, pp.1118-1145, 2015. ,
The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis, PloS One, vol.9, p.115103, 2014. ,
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma, Breast Cancer Res Treat, vol.169, pp.295-304, 2018. ,
, Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep, vol.9, p.9934, 2019.
Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, pp.2560-2566, 2000. ,
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis, Cancer, vol.106, pp.4-16, 2006. ,
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial, Lancet Oncol, vol.8, pp.881-889, 2007. ,
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.2694-702, 2005. ,
Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer, Br J Surg, vol.93, pp.539-585, 2006. ,
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients, Ann Surg, vol.250, pp.558-66, 2009. ,
Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study, Breast Cancer Res Treat, vol.173, pp.343-52, 2019. ,
Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, pp.726-758, 2009. ,
The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer, Ann Surg Oncol, vol.19, pp.3177-84, 2012. ,
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial, JAMA, vol.310, pp.1455-61, 2013. ,
Sentinel-lymphnode biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study, Lancet Oncol, vol.14, pp.609-627, 2013. ,
Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion, Breast Care Basel Switz, vol.10, pp.124-154, 2015. ,
Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer, J Breast Cancer, vol.20, pp.378-85, 2017. ,
Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer, Ann Surg Oncol, vol.23, pp.3501-3510, 2016. ,
Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy, Surg Today, 2019. ,
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.9304-9315, 2005. ,
Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy, Breast Cancer Res Treat, vol.176, pp.591-597, 2019. ,
Recherche sur les métastases microscopiques des ganglions lymphatiques parasternaux dans le cancer du sein, J Int Chir, pp.492-509, 1951. ,
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer, Med Oncol Northwood Lond Engl, vol.29, pp.1536-1578, 2012. ,
, ANNEXES Les annexes 1 représentent des diagrammes de Sankey prédisant l'atteinte ganglionnaire post opératoire en fonction du grade
, Annexe 1a : Le diagramme de Sankey est colorisé selon le stade TNM. Le stade T1 est colorisé en kaki, le stade T2 en bleu foncé
, Annexe 1b : Le diagramme de Sankey est colorisé selon le grade histologique. En rouge les grade I et II et en gris, les grade III
, Annexe 1e : Le diagramme de Sankey est colorisé selon l'atteinte ganglionnaire post-opératoire
, Les annexes 2 représentent des diagrammes de Sankey prédisant l'atteinte ganglionnaire post opératoire en fonction du grade
, Annexe 2a : Le diagramme de Sankey est colorisé selon le stade TNM. Le stade T1 est colorisé en kaki, le stade T2 en bleu foncé
, Annexe 2b : Le diagramme de Sankey est colorisé selon le grade histologique. En rouge les grade I et II et en gris, les grade III
, Annexe 2c : Le diagramme de Sankey est colorisé selon l'envahissement ganglionnaire. En gris, les Npré opératoire et en rouge, les N+ pré opératoire
, Annexe 2d : Le diagramme de Sankey est colorisé selon la réponse histologique mammaire
, Annexe 2e : Le diagramme de Sankey est colorisé selon l'atteinte ganglionnaire post-opératoire
, Les annexes 3 représentent des diagrammes de Sankey prédisant l'atteinte ganglionnaire post opératoire en fonction du grade
Le stade T1 est colorisé en kaki, le stade T2 en bleu foncé, et le stade T3 en bleu ciel Annexe 3b : Le diagramme de Sankey est colorisé selon le grade histologique. En rouge les grade I et II ,
, Annexe 3e : Le diagramme de Sankey est colorisé selon l'atteinte ganglionnaire post-opératoire
, Les annexes 4 représentent des diagrammes de Sankey prédisant l'atteinte ganglionnaire post opératoire en fonction du grade
, Annexe 4b : Le diagramme de Sankey est colorisé selon le grade histologique. En rouge les grade I et II et en gris, les grade III
, Annexe 4c : Le diagramme de Sankey est colorisé selon l'envahissement ganglionnaire. En gris, les Npré opératoire et en rouge, les N+ pré opératoire